This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review ourCookie Policy.

 

CD30 expression is variable across lymphomas and should be reported as a percentage

See labs
reporting CD30
down to 1%

Innovative labs that report CD30 percentage expression

The following labs recognize the value of the CD30 biomarker and report CD30 expression quantitatively as a percentage (vs a binary result of positive/negative) for hematologists-oncologists.

Print List
See who's on the list

Get on the list

Are you a lab medical director wanting to learn more about quantitative reporting? Interested in joining the list of labs reporting CD30 as a percentage? Contact us today to be added to this online resource.

Screening for CD30 by IHC helps in the differential diagnosis of certain lymphomas

Pathology resources:

Best practices for CD30 reporting and quality control

Download
Brochure

Pathology resources:

Best practices for CD30 reporting and quality control

Download
Brochure

Did you know?

CD30 reporting protocols

To aid in characterizing CD30 expression, Seagen recommends using the following descriptors in your pathology reports

Report descriptors
Definition
CD30 detected (≥1% expression)
Presence of ≥1% membranous and/or Golgi staining in tumor (neoplastic) cells. Staining at any intensity should be counted.

In cases where it is difficult to differentiate tumor cells from normal lymphocytes, use total lymphocytes as the denominator for determination of percentage
CD30 not detected (<1% expression)
Presence of <1% staining in tumor cells
Staining intensity
1+, 2+, 3+

IHC = immunohistochemistry.

References: 1. Federico M, Bellei M, Luminari S, et al. CD30+ expression in peripheral T-cell lymphomas (PTCLs): a subset analysis from the international, prospective T-Cell Project. J Clin Oncol. 2015;33(suppl 15):8552. 2.Delsol G, Falini B, Müller-Hermelink HK, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:312-316. 3.Mason DY, Harris NL, Delsol G, et al. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:317-319. 4.Takeshita M, Akamatsu M, Ohshima K, et al. CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology. 1995;26:539-546. 5.Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98:e81-82. 6. Pongpruttipan T, Kummalue T, Bedavanija A, et al. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multiparameter study from Thailand. Diagn Pathol. 2011;6:79. 7. Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695. 8. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33:1860-1868. 9.Cerroni L, Rieger E, Hödl S, Kerl H. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol. 1992;16:543-552. 10. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol. 2004;140:441-447.